Medical technology company HeartBeam Inc. has significantly strengthened its intellectual property portfolio by securing two new U.S. patents that promise to advance personalized cardiac care. The first patent covers a credit card-sized, cable-free 3D ECG device capable of real-time cardiac monitoring and symptom capture. This compact technology represents a significant leap forward in portable heart health monitoring, enabling patients to track their cardiac conditions outside traditional medical settings.
The second patent protects an advanced rhythm analysis algorithm designed to identify arrhythmias through continuous signal input. When the algorithm detects potential anomalies, it prompts users to collect 3D ECG data, providing a proactive approach to heart health management. With these additions, HeartBeam now holds 20 issued patents and has an additional 34 patents pending or approved. This expanded intellectual property collection positions the company strongly as it prepares for FDA review of its 12-lead ECG synthesis software.
The company's platform technology aims to revolutionize cardiac care by creating portable devices that can capture the heart's electrical signals from three dimensions. This innovation could potentially enable physicians to identify cardiac health trends and acute conditions more efficiently, directing patients to appropriate care outside medical facilities. These patent developments underscore HeartBeam's commitment to transforming cardiac health management through technological innovation, offering patients and healthcare providers more accessible and comprehensive heart monitoring solutions. The company's progress can be followed through its official website where additional information about their technology is available.
